Quality of any Active Pharmaceutical Ingredient (API) or drug product for patient compliance is directly depending on stability of drug. The ICH drug stability test guideline Q1A (R2) requires that analysis of stability samples should be done through the use of validated Stability indicating assay methods (SIAMs) that can detect the changes with time in the chemical, physical, or microbiological properties of the drug substance and drug product, and that are specific, so that the contents of active ingredient, degradation products, and other components of interest can be accurately measured without interference. A proactive approach in developing a SIAMs involve forced degradation at the early stages of development with the key degradation samples used in the method development process.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.